AnHorn Medicines is a novel drug discovery company with a strong pipeline, offering therapies that target and degrade disease-related proteins. Our mission is to develop new class of drugs BIGPRO® (Bi-functional liGand induced PROteolysis) under the foundation of Targeted Protein Degradation (TPD), to address a broad range of life-threatening and life-impairing diseases.
We focus on novel therapies for cancer, neurodegeneration, and aging diseases. We are turning innovation into new therapeutics – new opportunities to target difficult-to-treat diseases and diseases plagued by drug resistance.
Location: Taiwan, Taipei
Member count: 1-10
Founded date: 2020
Investors 1
| Date | Name | Website |
| 03.07.2021 | Taipei Ang... | taipeiange... |